Eomaia
Colostrum collection device for mothers and healthcare professionals
Highlights
- Young companyFounded 2022
- New on EvolcAdded 2026-11-04
About Eomaia
Eomaia makes Mammex, a device designed to help mothers express and collect colostrum. It is intended for situations including prematurity, caesarean birth, mother–baby separation and difficulty with immediate breastfeeding.
The device is presented for use by mothers and healthcare teams, including midwives, childcare nurses and neonatal teams. Mammex is available to buy, with a separate professional pathway offering documentation and quotes.
Eomaia is a French SAS founded in 2022 and headquartered in Nantes.
Product: Mammex, a device designed to facilitate colostrum expression and collection.
Jobs at Eomaia
More health & medtech companies
EOS imaging
Low dose 2D/3D medical imaging systems and orthopedic planning software for hospitals and orthopedic surgeonsEos Psy
Psychological consultations, assessments and training for individuals and organisations in Paris, in person or by videoNew on EvolcEpiconcept
SaaS software and epidemiology services for public health programmes: screening, vaccination and cohort managementNew on Evolcepitact.fr
Makes foot, knee, hand and leg-circulation orthoses and insoles sold direct to consumers through its online shopNew on EvolcEquasens
Healthcare software, connected devices and financing solutions for health professionals, care facilities and patientsNew on EvolcEquip' Sante
Sells and rents medical equipment and orthopedic products to individuals and healthcare professionals in FranceNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Frontend frameworks
- Next.jsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- ReactMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Related technologyimplied by Next.js
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.